Suppr超能文献

一名接受类固醇治疗并发生椎体骨折儿童的骨密度和骨质量变化趋势:病例报告

Bone Mineral Density and Bone Quality Trends in a Child on Steroid Therapy Who Developed a Vertebral Fracture: A Case Report.

作者信息

Aoyagi Jun, Kanai Takahiro, Ito Takane, Ishii Marika, Tajima Toshihiro

机构信息

Department of Pediatrics, Jichi Medical University, Shimotsuke, JPN.

出版信息

Cureus. 2025 Apr 21;17(4):e82675. doi: 10.7759/cureus.82675. eCollection 2025 Apr.

Abstract

Glucocorticoids (GCs) are commonly used to treat kidney problems in children and usually work well, but they can sometimes cause bone thinning, which may lead to fractures in the spine. Despite this, there is currently no established clinical approach for managing GC-induced osteoporosis (GIOP) in pediatric patients, highlighting the need for more data. Bone strength reflects both bone mineral density (BMD) and bone quality, with BMD assessed by X-ray and bone quality evaluated through serum or urine bone turnover markers (BTMs). In this case, a seven-year-old girl diagnosed with Henoch-Schönlein purpura nephritis was monitored over a two-year period during steroid treatment. Her BMD and serum BTMs, including alkaline phosphatase (ALP), tartrate-resistant acid phosphatase 5b (TRACP-5b), and undercarboxylated osteocalcin (ucOC), were tracked throughout the course. One month after initiating steroid therapy, her serum ALP (S-ALP) level decreased by 27.1% from baseline, while serum TRACP-5b (S-TRACP-5b) and serum ucOC increased by 34.4% and 52.3%, respectively, although BMD remained unchanged. Two months into treatment, she developed thoracic vertebral fractures (VFs) and was diagnosed with GIOP, prompting the initiation of oral alendronate sodium hydrate. Following the introduction of antiresorptive therapy and a reduction in GC dosage, both S-ALP and S-TRACP-5b levels returned to baseline by six months, accompanied by an 8.8% increase in BMD compared to the one-month level. No further fractures were observed after the cessation of antiresorptive treatment, which was guided by serial monitoring of BMD and BTMs. This case underscores the association of VFs with a decline in bone formation markers and elevations in bone resorption and matrix-related markers and demonstrates how BTMs reflecting bone quality can aid in determining the optimal duration of antiresorptive treatment in pediatric patients with GIOP.

摘要

糖皮质激素(GCs)常用于治疗儿童肾脏问题,通常效果良好,但有时会导致骨质变薄,这可能会引发脊柱骨折。尽管如此,目前尚无针对儿科患者糖皮质激素诱导的骨质疏松症(GIOP)的既定临床管理方法,这凸显了获取更多数据的必要性。骨强度反映了骨矿物质密度(BMD)和骨质量,其中BMD通过X射线评估,骨质量通过血清或尿液骨转换标志物(BTMs)进行评估。在此案例中,一名七岁被诊断为过敏性紫癜性肾炎的女孩在接受类固醇治疗的两年期间接受了监测。在整个过程中,对她的BMD和血清BTMs进行了跟踪,包括碱性磷酸酶(ALP)、抗酒石酸酸性磷酸酶5b(TRACP-5b)和未羧化骨钙素(ucOC)。开始类固醇治疗一个月后,她的血清ALP(S-ALP)水平较基线下降了27.1%,而血清TRACP-5b(S-TRACP-5b)和血清ucOC分别升高了34.4%和52.3%,尽管BMD保持不变。治疗两个月后,她出现了胸椎骨折(VFs)并被诊断为GIOP,于是开始口服阿仑膦酸钠水合物。在引入抗吸收治疗并减少GC剂量后,S-ALP和S-TRACP-5b水平在六个月时恢复到基线,与治疗一个月时相比,BMD增加了8.8%。在以BMD和BTMs的连续监测为指导停止抗吸收治疗后,未观察到进一步的骨折。该案例强调了VFs与骨形成标志物下降以及骨吸收和基质相关标志物升高之间的关联,并展示了反映骨质量的BTMs如何有助于确定儿科GIOP患者抗吸收治疗的最佳持续时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a368/12093281/d695535cf372/cureus-0017-00000082675-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验